The HIB-202-101 study is a lupus nephritis clinical trial testing an investigational drug for adults with lupus nephritis. The goal is to assess the safety and tolerability of the study drug, felzartamab, as a potential treatment for lupus nephritis.
You may be eligible to join the study if you meet the following requirements*:
- 18 to 75 years old
- Confirmed diagnosis of Class 3 or 4 lupus nephritis (with or without Class 5) with a kidney biopsy
- Lack of response to standard of care therapies for lupus nephritis
See if you may qualifyThe HIB-202-101 study is a 2-part study that lasts about a total of 2 years. Part 1 must be completed to be eligible for Part 2.
If you choose to participate, you can expect the following steps:
1) Screening
You will complete screening assessments at the study clinic to determine if you qualify for the study.
2) Treatment period
You will receive 1 intravenous (IV) infusion of the study medication at each of the 9 study clinic visits. You will also receive premedication before infusions to help reduce the chance of a reaction.
3) Off-treatment period
You will visit the study clinic regularly for continued study assessments to monitor how your body and the lupus nephritis respond to the study medication.
4) Repeat steps 2-3
You will receive 9 more IV infusions of the study medication followed by 5 more follow-up visits for continued study assessments.
1) Screening
You will complete screening assessments at the study clinic to determine if you qualify for the study.
2) Treatment period
You will receive 1 intravenous (IV) infusion of the study drug at each of the 9 study clinic visits. You will also receive a medication before infusions to help reduce the chance of a reaction.
3) Off-treatment period
You will visit the study clinic regularly for continued study assessments to monitor how your body and the lupus nephritis respond to the study drug.
4) Repeat steps 2-3
You will receive 9 more IV infusions of the study drug followed by 5 more follow-up visits for continued study assessments.
Participation in a clinical study is voluntary. You can ask any questions you have and may leave the study at any time, for any reason.
*Other study requirements will apply
